Count on us for updates on the coronavirus and guidance for cancer patients and family members.Read the latest articles
Dr. Philip A. Thompson is an assistant professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center in Houston, Texas. Dr. Thompson received his Bachelor of Medicine and Bachelor of Surgery (MB, BS) in Hematology from the University of Melbourne, Australia. He is the recipient of several honors and awards, including Research Fellow of the Year, ASH abstract achievement award, and Celgene’s Future Leaders in Hematology award. Dr. Thompson has authored and co-authored more than 50 peer-reviewed original research articles, invited articles, editorials and abstracts.
Dr. Thompson is dedicated to developing curative strategies for the treatment of leukemia. His focus has been predominantly on clinical research in CLL and Richter transformation (RT). His specific interest is in the validation of pre-treatment, predictive genomic markers for disease response in CLL and RT, and the validation of biomarkers during therapy which can direct therapeutic decision-making, particularly the optimization of minimal residual disease (MRD) analysis. Dr. Thompson has received research support from Pharmacyclics, Abbvie, Amgen and Acerta Pharma. He is an advisory board member for Pharmacyclics.